Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 6,100 shares, a drop of 57.9% from the March 31st total of 14,500 shares. Based on an average daily volume of 14,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the company’s stock are sold short.

Artelo Biosciences Stock Performance

Shares of ARTL opened at $1.34 on Friday. The firm has a market capitalization of $4.33 million, a price-to-earnings ratio of -0.43 and a beta of 1.45. The firm’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $1.43. Artelo Biosciences has a twelve month low of $1.15 and a twelve month high of $2.98.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Monday, March 25th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.70). On average, analysts predict that Artelo Biosciences will post -2.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a research report on Tuesday, April 2nd.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD.